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Background: The purpose of this study is to confirm whether the serum prolactin cut-off value is definitive to
distinguish prolactinoma and non-functioning pituitary adenoma with hyperprolactinemia. We retrospectively
reviewed patients with non-functioning pituitary adenoma, including gonadotroph cell adenoma, null cell adenoma
and prolactinoma who were surgically treated at Kohnan hospital between June 2005 and March 2012. The patients
without endocrinological/neurological symptom and with the tumor larger than 40 mm in diameter were excluded.
According to previously reported cut-off value of serum prolactin, mild hyperprolactinemia, which is considered
non-definitive (border zone) concentration between prolactinoma and non-functioning pituitary adenoma, were
defined as 90 – 200 ng/ml. Ninety-five prolactinoma patients and 212 patients with non-functioning pituitary
adenoma were analyzed. The serum prolactin concentration, tumor size, and clinical characteristics were statistically
compared.
Results: Receiver operating characteristic (ROC) curve analysis was performed, indicating that cut-off value of
serum prolactin concentration to distinguish between non-functioning pituitary adenoma and prolactinoma was
38.6 ng/ml. Although it was statistically good accuracy (the area under the curve; 0.96, sensitivity; 0.99 and
specificity; 0.81), the result did not fit the clinical situation as many false-positive cases (40 of 212, 18.9%) were
included. Among them, mild hyperprolactinemia were shown in 9 (4.2%) and 53 (55.8%) non-functioning pituitary
adenoma and prolactinoma, respectively. Four of 9 border zone patients with non-functioning pituitary adenoma
were initially treated with dopamine agonists. Sequential head magnetic resonance imaging revealed no tumor
shrinkage in all of them despite serum prolactin concentration was decreased. Surgery was chosen for them
24.6 months in average after the introduction of medication.
Conclusions: Non-negligible number of patients with non-functioning pituitary adenoma presented unexpectedly
high concentration of prolactin, fraught with a potential risk of misdiagnosis. While this equivocal population is not
the majority, the prolactin cut-off value is not safely applicable. Especially for the patients with border zone prolactin
concentration, meticulous follow up with sequential pituitary imaging is important.
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Hyperprolactinemia has been associated with a large num-
ber of etiologies, such as certain medication, autoimmune
disease, and sellar tumors. Pituitary adenoma is one of the
most frequent causes of hyperprolactinemia, and prolacti-
noma accounts for a high proportion of hyperprolactine-
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article, unless otherwise stated.Non-functioning pituitary adenoma is another etiology of
hyperprolactinemia, which is induced by compression of
the pituitary stalk.
Medical treatment with dopamine agonists (DAs) is
highly effective for most cases, so that is widely accepted
as the first line of treatment for hyperprolactinemia. In
spite of the strong suppression of serum prolactin level,
DAs usage has several disadvantages when used for pa-
tients with prolactinoma. Intolerance and residence have
been reported in some patients [1,2], and DAs are re-
ported as a potential predisposing factor for pituitarytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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able about the effects of continuous DAs usage on fetal
development [4,5]. Furthermore, DAs can normalize the
serum prolactin level in patients with non-functioning
pituitary adenoma presented with hyperprolactinemia
by inhibition of the normal pituitary function, but there
is no chance for tumor regression. So surgical treat-
ment can be a considerable treatment option for some
patients with large pituitary adenoma presented with
hyperprolactinemia.
To decide the treatment options, discrimination of the
cause for hyperprolactinemia is important. Small tumors
presented with hyperprolactinemia could be considered
prolactinoma in majority of the cases, so that it is not so
difficult making correct diagnosis. However, differential
diagnosis of large non-functioning pituitary adenoma
and prolactinoma is sometimes very difficult despite se-
veral endocrinological loading tests and radiographical
assessments have been evaluated [6]. Although recent
reports indicated the endocrinological discrimination of
non-functioning pituitary adenoma from prolactinoma,
the cut-off value of serum prolactin concentration be-
tween them varied widely from 94 to 200 ng/ml and
there are no definitive diagnostic criteria [6-8].
In this study, we retrospectively reviewed the patients
with prolactinoma and non-functioning pituitary adeno-
ma presented with hyperprolactinemia to confirm whe-
ther the serum prolactin cut-off value is definitive to
distinguish them. The characteristics of clinical course
and management for these patients were discussed.
Methods
Participants
We retrospectively reviewed patients with non-functioning
pituitary adenoma, including gonadotroph cell adenoma
and null cell adenoma, and prolactinoma who were surgi-
cally treated at Kohnan hospital between June 2005 and
March 2012. Most patients with prolactinomas were re-
ferred from the endocrinological or gynecological clinics.
During this period, 724 cases were treated with transsphe-
noidal surgery, performed by single surgeon (Y.O.). Among
them, 95 (13.1%) patients with prolactinoma and 212
(29.3%) patients with non-functioning pituitary adenoma
were analyzed.
Surgical indication for prolactinoma
Surgery was indicated for the patients who required
skull base reconstruction to prevent cerebrospinal fluid
leakage, and who already presented severe visual distur-
bance. Patients with small tumor without endocrinolo-
gical and neurological symptoms were not included.
Otherwise, we propose both medical treatment and sur-
gery as treatment options. The advantage and disadvan-
tage of them were equivalently explained. Surgery wasperformed for patients who understood and chose surgi-
cal treatment by themselves. Informed consent was ob-
tained from each patient or guardian on admission, and
prior to surgery.Data collection
The following variables were recorded in a database and
analyzed: age, sex, histological diagnosis, pretreatment
serum concentration of anterior pituitary hormones in-
cluding prolactin, and the maximum diameter of the tu-
mors. Normal range of serum prolactin concentration
in our hospital was 4.29 - 13.69 ng/ml in men, 4.91 -
29.32 ng/ml in premenopausal women, and 3.12 -
15.39 ng/ml in postmenopausal women.Clinical management
On admission, the general physiological examination
and magnetic resonance (MR) imaging were performed
and basal value of serum anterior pituitary hormones
were examined prior to surgery in all patients. If patients
had already treated with dopamine agonist, administra-
tion was stopped several weeks before the surgery. In
such cases, preoperative highest value of serum prolactin
was considered as the initial prolactin value. After re-
quired examination, transsphenoidal adenomectomy was
performed and the surgical specimens were proceeded
for histopathological examination. Pathology review was
performed based on World Health Organization classifi-
cation 2004 [9].Determination of the cut-off value of serum prolactin
concentration and definition of border zone patients with
mild hyperprolactinemia
To identify the cut-off value of serum prolactin level, re-
ceiver operating characteristic (ROC) curve analysis was
performed with JMP-pro software (SAS Institute Japan,
Tokyo, Japan). According to the previous reports, mild
hyperprolactinemia, which is considered non-definitive
concentration between prolactinoma and non-functioning
pituitary adenoma, were defined as 90 – 200 ng/ml
[8,10,11]. The patients with serum prolactin concentration
in this range were considered as border zone cases.Statistical analysis
The means and standard deviations (SDs) for serum
prolactin concentration was calculated and compared
with Student’s t-test or Fisher’s exact test. Probability
values < 0.05 were considered statistically significant.
SPSS software (IBM Japan, Tokyo, Japan) were used
for statistical analyses.
Table 1 Demographic characteristics of the total study population
Characteristic Non-functioning adenoma Prolactinoma P value
Age, years old Range (median) 23-80 (60) 14-82 (38) < 0.001*
Sex Male (%) 98 (46.2) 20 (21.1) 0.05
Female (%) 114 (53.8) 75 (78.9) -
Tumor size Maximum Diameter (mean ± SD, mm) 23.4 ± 6.3 15.4 ± 9.0 < 0.001*
Serum prolactin concentration (mean ± SD, ng/ml) 28.4 ± 32.1 747.0 ± 1548.9 < 0.001*
*statistically significant.
SD, standard deviation.
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Patient characteristics
The characteristics of patients with non-functioning pi-
tuitary adenoma and prolactinoma were summarized in
Table 1. The age of patients with non-functioning pituit-
ary adenoma was higher than with prolactinoma (p <
0.001). The tumor size of non-functioning pituitary ad-
enoma was larger than prolactinoma (p < 0.001). Pre-
operative serum prolactin concentrations was 28.4 ± 32.1
and 747.0 ± 1548.9 ng/ml (mean ± SD) in patients with
non-functioning pituitary adenoma and prolactinoma,
respectively. There was statistically significant difference
in the mean value of prolactin between the two groups
(p < 0.001).Serum prolactin concentration and patient distribution
The patient distribution according to serum prolactin
concentration was shown in Figures 1 and 2. In 212
patients with non-functioning pituitary adenoma, most
patients presented between 10 to 20 ng/ml of serum
prolactin concentration and the highest prolactin value
was 284.9 ng/ml (Figure 1). In 95 patients with prolac-
tinoma, most of them presented serum prolactin con-
centration around 100 ng/ml and 53 (55.8%) of them
presented the serum prolactin concentration less than
200 ng/ml. Seventeen (18.0%) patients presented the
serum prolactin concentration over 1000 ng/ml resulting
in raising the mean value (Figure 2).Figure 1 Frequency distribution according to serum prolactin
concentration in patients with non-functioning pituitary
adenoma. Serum prolactin concentration in most patients was
around 10 to 20 ng/ml. Nine (4.2%) patients presented the serum
prolactin concentration higher than 90 ng/ml (the dark bar graph).Determination of the cut-off value of serum prolactin
concentration
ROC curve analysis was performed for all cases (Figure 3).
The area under the curve was 0.96, which indicated high
accuracy of diagnostic value. According to this analysis,
cut-off value of serum prolactin concentration to distin-
guish between non-functioning pituitary adenoma and
prolactinoma was 38.6 ng/ml. Sensitivity and specificity
were 0.99 and 0.81, respectively. However, this result did
not fit the clinical situation, because 40 (18.9%) of 212
patients with non-functioning pituitary adenoma were
false-positive. We further analyzed patients whose serumprolactin concentration was between 90 and 200 ng/ml,
according to previous reports [8,10,11]. This range was
considered as the border zone of differential diagnosis.Characteristics of patients with mild hyperprolactinemia
(Table 2)
Nine (4.2%) patients with non-functioning pituitary
adenoma and 53 (55.8%) prolactinoma patients were
considered as the border zone cases for differential diag-
nosis. Table 2 showed the summary of these them. There
were no statistical differences in serum prolactin con-
centration (141.3 ± 68.2 vs. 144.5 ± 31.9, p = 0.84), and
age (39 vs. 34, p = 0.12). Tumor size was smaller in pro-
lactinoma group (22.0 ± 6.0 vs. 12.2 ± 6.8, p = 0.01).
Figure 2 Frequency distribution according to serum prolactin
concentration in patients with prolactinoma. Serum prolactin
concentration in most patients was around 100 ng/ml. Fifty-three
(55.8%) patients presented the serum prolactin concentration lower
than 200 ng/ml (38.56 – 197.7 ng/ml) (the dark bar graph).
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dopamine agonist
Among the patients with non-functioning pituitary aden-
oma, 4 patients were initially treated with dopamine agon-
ist. The maximum tumor diameter ranged 10 to 31 mm.
Serum prolactin concentration before medication ranged
62.41 to 130 ng/ml and was well suppressed in other 3Figure 3 Receiver operating characteristic (ROC) curve analysis
shows that serum prolactin concentration has a high accuracy
for differentiating between prolactinoma and non-functioning
pituitary adenoma with hyperprolactinemia.patients except for one patient who did not continue
medication for some reason. All of them were followed
with MR imaging every 6 months. Nevertheless, tumor
shrinkage was not achieved in three patients or visual dis-
turbance was aggravated in one patient in her clinical
course.
Discussion
DAs are the first line of treatment for hyperprolactine-
mia, which is one of the most frequent endocrinological
disorders, especially in young women. As the patients
present with gonadal dysfunctions and resulted in infer-
tility [6,12], treatment for hyperprolactinemia is quite
important in clinical aspect [13]. DAs have strong sup-
pressive effects on serum prolactin level regardless of
etiology, so they tend to be used for both patients with
prolactinoma and non-functioning pituitary adenoma with
hyperprolactinemia. The mechanism of DAs is quite
specific for prolactin normalization. The agents act by
binding to specific dopamine receptors on the prolactin-
secreting cells, resulting in reduced synthesis and se-
cretion of prolactin, and adenoma cell size [14]. Thus,
treatment with DAs can decrease tumor size in about
90% of patients with prolactinoma [15]. In addition,
the prolactin-inhibiting mechanism can affect not only ad-
enoma cells but also normal prolactin-secreting cells. So,
DAs can normalize the serum prolactin concentration in
patients with non-functioning pituitary adenoma, but
there is no chance for tumor regression. In clinic, patients
with “high” concentration of serum prolactin are usually
started treatment with DAs. In this study, we confirmed
whether the serum prolactin cut-off value is reasonable to
identify who should be treated with DAs.
First, we performed the ROC curve analysis to assess
the cut-off value of serum prolactin concentration. This
statistical analysis showed good correlation between se-
rum prolactin level and prolactinoma diagnosis. The cut-
off value was 38.6 ng/ml with acceptable sensitivity and
specificity. However, this result did not fit the clinical situ-
ation, as many false-positive cases were included. Such
cases have a risk of inappropriate treatment with DAs.
The problem still remains to discriminate prolactinoma
from non-functioning pituitary adenoma simply with
serum prolactin cut-off value.
Previously, several studies have been examined the
threshold of serum prolactin concentration to distinguish
them. Karavitaki et al. advocated the cut-off value of
serum prolactin was 94 ng/ml [8]. Other reports showed
that the serum prolactin values were less than 200 ng/ml
in most patients with non-functioning pituitary adenoma
[10,11]. Compared to them, 9 (4.2%) patients in our series
presented the serum prolactin concentration higher than
90 ng/ml in non-functioning pituitary adeonmas, and
53 (55.8%) of prolactinoma patients presented mild
Table 2 Characteristics of patients with mild hyperprolactinemia
Characteristic Non-functioning adenoma(PRL >90 ng/ml)
Prolactinoma
(PRL <200 ng/ml) P value
Number of patients 9 53
Age, years old Range (median) 35-67 (39) 14-82 (34) 0.12
Tumor size Maximum Diameter (mean ± SD, mm) 22.0 ± 6.0 12.2 ± 6.8 0.01*
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tion has to be paid for this border zone group. In our
series, 4 patients with non-functioning pituitary aden-
oma were initially treated with dopamine agonist. All
of them were in the border zone group, whose serum
prolactin concentration before medication ranged 62.41
to 130 ng/ml.
Taken together, the serum prolactin cut-off value is
not safely applicable to establish a correct diagnosis in
patients with large pituitary adenoma, nevertheless tu-
mor size is smaller in prolactinoma than non-functioning
pituitary adenoma in general population and border zone
patients (Tables 1 and 2). As mentioned above, DAs were
introduced to 4 patients with non-functioning pituit-
ary adenoma for initial treatment. They showed good
result of serum prolactin reduction but no effects on
tumor shrinkage. As the monitoring of serum prolac-
tin alone is not sufficient to evaluate the treatment efficacy
in such cases, meticulous radiographical follow up is quite
important.
Another principle is when to decide the surgical indi-
cation. Olafsdottir et al. reported that more than 90% of
prolactinoma decreased in size at least 24 months treat-
ment with dopamine agonist [16]. They also reviewed
that longer usage of dopamine agonists showed with
higher response rate for serum prolactin normalization
and in patients with prolactinoma treated with cabergo-
line, 75 to 100% of prolactin normalization was achieved
within 24 months. In our series, patients with non-
functioning pituitary adenoma who were treated with
dopamine agonist did not show tumor shrinkage, and
surgery underwent for them 24.6 months after intro-
duction of medication, on average. Moreover, the usage
of dopamine agonists is one of the risk factors of pituit-
ary apoplexy [17-20] and the hemorrhagic event is more
frequent within 18 months since the beginning of dopa-
mine agonist treatment [21]. Taken together, patients
with hyperprolactinemia who were treated with dopa-
mine agonist should be meticulously followed with MR
imaging at least 24 months. When the neurological de-
terioration or no tumor shrinkage was evident, surgery
should be considered.The present study has several limitations. The pa-
tients with pituitary tumor who were successfully trea-
ted with dopamine agonist did not include because of
lack of histological verification. Also, we did not assess
the possibility of macroprolactinemia. However, patients
without clinical symptoms were not indicated for any
treatment even if the serum prolactin concentration was
high, and such cases were not included in this study.
More other factors such as sex and tumor size can be
considered as the indicative variables for prolactinoma
diagnosis. For statistical multivariate analysis, more case
accumulation is required. We excluded giant adenomas,
because the treatment is still challenging for this en-
tity and outcome is still poor [22]. The treatment stra-
tegy is not well established for giant adenomas. More
cases are required for better understanding of diagnostic
criteria.Conclusions
This study indicated that 4.2% of patients with hy-
perprolactinemia harboring non-functioning pituitary
adenoma had a risk of misdiagnosis. As the serum pro-
lactin level could not be definitive, these patients should
be followed up with neuroimaging to ensure that the
optimum timing for neurosurgical intervention is not
missed, even if the primary purpose of gonadal restor-
ation has been achieved with medical treatment. DAs
are strong and reliable treatment for patients with
hyperprolactinemia, but surgery should be considered
for patients with suboptimal results following medical
treatment.Ethics
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